On this page of StockholderLetter.com we present the latest annual shareholder letter from ImmunityBio, Inc. — ticker symbol IBRX. Reading current and past IBRX letters to shareholders can bring important insights into the investment thesis.
Annual Report 2024
About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company s range of immunotherapy platforms, alone and together, act to drive an immune response with the goal of creating durable immune memory generating safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit ImmunityBio.com (Founder s Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Our Approved Product ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells NK and CD8+ killer T cells that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15R , which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA, which confers stability and longer half-life than recombinant or native IL-15, mimics the natural biological properties of the membrane-bound IL-15R , delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for use in the United States with BCG for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without papillary tumors. For more information, visit ImmunityBio.com (Founder s Vision) and Anktiva.com.
 • shareholder letter icon 4/29/2025 Letter Continued (Full PDF)
 • stockholder letter icon 4/28/2023 IBRX Stockholder Letter
 • stockholder letter icon 4/29/2024 IBRX Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon IBRX Benford's Law Stock Score = 75


IBRX Shareholder/Stockholder Letter Transcript:

Annual Report

2024


About ImmunityBio
ImmunityBio is a vertically-integrated commercial stage biotechnology company developing
next-generation therapies and vaccines that bolster the natural immune system to defeat
cancers and infectious diseases. The Company   s range of immunotherapy platforms, alone and
together, act to drive an immune response with the goal of creating durable immune memory
generating safe protection against disease. We are applying our science and platforms to
treating cancers, including the development of potential cancer vaccines, as well as developing
immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for
standard high-dose chemotherapy. These platforms and their associated product candidates
are designed to be more effective, accessible, and easily administered than current standards of
care in oncology and infectious diseases. For more information, visit ImmunityBio.com
(Founder   s Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.
Our Approved Product     ANKTIVA  
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the
development, maintenance, and function of key immune cells   NK and CD8+ killer T cells   that
are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor
escape phase of clones resistant to T cells and restores memory T cell activity with resultant
prolonged duration of complete response.
ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of an
IL-15 mutant (IL-15N72D) fused with an IL-15R  , which binds with high affinity to IL-15
receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA, which confers
stability and longer half-life than recombinant or native IL-15, mimics the natural biological
properties of the membrane-bound IL-15R  , delivering IL-15 by dendritic cells and drives the
activation and proliferation of NK cells with the generation of memory killer T cells that have
retained immune memory against these tumor clones. The proliferation of the trifecta of these
immune killing cells and the activation of trained immune memory results in immunogenic cell
death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved
pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor
activity compared to native, non-complexed IL-15 in-vivo.
ANKTIVA was approved by the FDA in 2024 for use in the United States with BCG for the
treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with
CIS with or without papillary tumors. For more information, visit ImmunityBio.com (Founder   s
Vision) and Anktiva.com.




shareholder letter icon 4/29/2025 Letter Continued (Full PDF)
 

IBRX Stockholder/Shareholder Letter (ImmunityBio, Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.